Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.51 |
| ▸ | ACACA | Q13085 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | NAPEPLD | Q6IQ20 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392809 | 1.00 | ACACB (0.51) | ACACBACACAKDM4EALDH1A1GAA | |
| SCHEMBL4395489 | 0.95 | ACACB (0.52) | ACACBACACAKDM4EALDH1A1GAA | |
| SCHEMBL4395481 | 0.95 | ACACB (0.52) | ACACBACACAKDM4EALDH1A1GAA | |
| SCHEMBL4395558 | 0.93 | ACACB (0.54) | ACACBACACAKDM4EALDH1A1GAA | |
| SCHEMBL4395569 | 0.93 | ACACB (0.54) | ACACBACACAKDM4EALDH1A1GAA | |
| SCHEMBL4394883 | 0.92 | ACACB (0.55) | ACACBACACAKDM4EALDH1A1GAA | |
| SCHEMBL4394891 | 0.92 | ACACB (0.55) | ACACBACACAKDM4EALDH1A1GAA | |
| SCHEMBL4391583 | 0.90 | ACACB (0.54) | ACACBACACAKDM4EALDH1A1GAA | |
| SCHEMBL4391594 | 0.90 | ACACB (0.54) | ACACBACACAKDM4EALDH1A1GAA | |
| SCHEMBL13768280 | 0.89 | ACACB (0.53) | ACACBACACAKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885KDM4E 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.